CompBrief BY VELARION

Companies Traws Pharma, Inc.

Traws Pharma CEO salary & total pay, FY2025: $1.4M

Traws Pharma (TRAW) CEO salary, fiscal 2025: D. Iain Dukes was paid a salary of $539,000 and $1,401,924 in total compensation. Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Traws Pharma, Inc.’s executive pay brief as a PDF

You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

Also free: The Pay Desk, the weekly executive pay briefing.

D. Iain Dukes's complete compensation dossier

A PDF and a CSV sent to your email: D. Iain Dukes's pay in every fiscal year Traws Pharma, Inc. reported it, line by line, with D. Iain Dukes's equity grants and Traws Pharma, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$1,401,924CEO D. Iain Dukes · source
Say-on-pay support96.36%Latest vote · source

CEO pay, last three years

  • $1,106,747FY2023
  • $647,582FY2024
  • $1,401,924FY2025

CEO total pay was $1,401,924 in fiscal 2025 (D. Iain Dukes), up from $647,582 in fiscal 2024 (Werner Cautreels, the CEO that year).

FY2025: salary $539,000 · bonus $237,375 · stock awards $86,077 · option awards $539,472

Executives and directors

Frequently asked questions

Who was the highest-paid executive at Traws Pharma, Inc. in fiscal 2025?
As disclosed, D. Iain Dukes (Chief Executive Officer) was the highest-paid executive at Traws Pharma, Inc. in fiscal 2025, with total compensation of $1,401,924.
How did shareholders vote on Traws Pharma, Inc.'s executive compensation?
As disclosed, 96.36% of shareholders supported Traws Pharma, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Traws Pharma, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Traws Pharma, Inc. reported total board compensation of $459,474 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
D. Iain Dukes$539,000$237,375$86,077$539,472$0$0$0$1,401,924
Chief Executive Officer
Charles Pauza500,000180,00043,037269,6960021,3071,014,040
Chief Science Officer
Nikolay Savchuk350,000126,00038,256220,554000734,810
Chief Operating Officer
Werner Cautreels166,577011,356118,8010057,163353,897
Former Chief Executive Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
D. Iain Dukes$1,401,924———
Charles Pauza1,014,040———
Nikolay Savchuk734,810———
Werner Cautreels353,897647,582—↓ −293,685

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The Company's executive compensation program reflects a variable pay-for-performance philosophy, utilizing several performance measures to align executive compensation with Company performance and seeking to incentivize long-term performance.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultant—
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingfalse
Equity grants and outstanding awards

No plan-based awards are on file for this fiscal year.

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
Charles PauzaRSU—2,925—$3,305
Charles PauzaOption—32,4063.01—
Charles PauzaOption—1,0542.33—
Charles PauzaOption—72,8322.33—
Charles PauzaRSU—18,471—20,872
Charles PauzaOption20,130—0.25—
Charles PauzaOption13,326—1.75—
D. Iain DukesRSU—2,025—2,288
D. Iain DukesOption—33,2223.01—
D. Iain DukesOption—31,6173.01—
D. Iain DukesOption—147,7712.33—
D. Iain DukesRSU—36,943—41,476
D. Iain DukesOption152,116—1.75—
Nikolay SavchukRSU—2,025—2,288
Nikolay SavchukOption—22,4353.01—
Nikolay SavchukOption—13,9352.33—
Nikolay SavchukOption—51,7412.33—
Nikolay SavchukRSU—16,419—18,553
Nikolay SavchukOption152,116—1.75—
Werner CautreelsRSU—6,000—6,780
Werner CautreelsOption—23,0001.65—
Werner CautreelsOption—11,5303.01—
Werner CautreelsOption—19,4962.33—
Werner CautreelsRSU—4,874—5,508
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Jack E. StoverIndependent · Audit (Chair) · Compensation · Nominating and Corporate Governance$196,500$14,346$130,041$0$0$340,887
M. Teresa ShoemakerIndependent · Audit · Compensation (Chair) · Nominating and Corporate Governance71,50014,346130,04100215,887
Trafford Clarke, Ph.DIndependent · Audit · Compensation · Nominating and Corporate Governance (Chair)69,50014,346130,04100213,887
Werner Cautreels, Ph.DNot independent45,00011,356118,08100174,437
John Leaman, M.DIndependent · Audit · Newly elected13,1259,45565,1530087,733
Nikolay Savchuk, Ph.DEmployee director—————0
Iain Dukes, D. PhilEmployee director—————0

Board fee structure and ownership guideline

Annual cash retainer$45,000
Annual equity retainer$28,400
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)15,000 / 10,000 / 8,000
Stock ownership guideline—

Total cost of the board

ComponentFY2025
Cash retainers and fees$395,625
Equity awards (grant-date value)$63,849
All other compensation$0
Total cost of the board$459,474

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Traws Pharma as a peer

Companies that benchmark against TRAW

The list of companies that name TRAW as a peer is temporarily unavailable — recheck shortly.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Traws Pharma, Inc.2025D. Iain Dukes$539,000$86,077$539,472$0$1,401,924

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-11-212,293,94986,56022,68696.36%Passed
20242024-10-312,177,24525,5272,98398.84%Passed
20232023-08-104,959,0161,066,808900,57882.3%Passed
20222022-08-184,976,9231,531,655405,58876.47%Passed
20212021-07-302,746,8711,014,427724,47473.03%Passed
20192019-06-171,436,117949,02722,54060.21%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20252025-11-2196.36%a
20242024-10-3198.84%b
20232023-08-1082.3%c

a. Approved under the standard stated in the filing — “Vote Required for Approval The affirmative vote of the holders of shares of common stock representing a majority of the votes cast on the matter is required for the approval, on a non-binding advisory basis, of the compensation paid to our named executive officers and adoption of the foregoing resolution in accordance with this Proposal No. || Abstentions: Broker non-votes (if any) and abstentions will not be counted as votes cast on the matter and will have no effect on the outcome of this proposal.”.

b. Approved under the standard stated in the filing — “Advisory Vote on Executive Compensation The approval, on an advisory basis, of the compensation of our named executive officers requires the affirmative vote of a majority of the votes cast at the Annual Meeting. || Abstentions: Abstentions are not considered to be votes cast and will have no effect on the outcome of the vote.”.

c. Approved under the standard stated in the filing — “Abstentions are not considered to be votes cast and will have no effect on the outcome of the vote.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Werner CautreelsDirector2026-07-09A14,150$0$0Derivative, Class A CommonForm 4 ↗
D. Iain DukesDirector2026-07-09A274,00000Derivative, Class A CommonForm 4 ↗
Trafford ClarkeDirector2026-07-09A14,15000Derivative, Class A CommonForm 4 ↗
John Harold LeamanDirector2026-07-09A14,15000Derivative, Class A CommonForm 4 ↗
M. Teresa ShoemakerDirector2026-07-09A14,15000Derivative, Class A CommonForm 4 ↗
Charles Nolan ParkerChief Financial Officer2026-07-09A90,00000Derivative, Class A CommonForm 4 ↗
Robert RedfieldChief Medical Officer2026-07-09A84,00000Derivative, Class A CommonForm 4 ↗
Nikolay SavchukDirector2026-07-09A93,00000Derivative, Class A CommonForm 4 ↗
Charles PauzaChief Science Officer Virology2026-07-09A97,00000Derivative, Class A CommonForm 4 ↗
Jack E. StoverDirector2026-07-09A14,15000Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

Sources (27 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, D. Iain Dukes. DEF 14A, filed 2026-05-29. Section “Executive Compensation” · page 45. As printed: 1,401,924. View filing ↗
  • Section 01, Charles Pauza. DEF 14A, filed 2026-05-29. Section “Executive Compensation”. As printed: 1,014,040. View filing ↗
  • Section 01, Nikolay Savchuk. DEF 14A, filed 2026-05-29. Section “Executive Compensation”. As printed: 734,810. View filing ↗
  • Section 01, Werner Cautreels. DEF 14A, filed 2026-05-29. Section “Executive Compensation”. As printed: 353,897. View filing ↗
  • Section 08, Jack E. Stover. DEF 14A, filed 2026-05-29. Section “Director Compensation”. As printed: 340,887. View filing ↗
  • Section 08, M. Teresa Shoemaker. DEF 14A, filed 2026-05-29. Section “Director Compensation”. As printed: 215,887. View filing ↗
  • Section 08, Trafford Clarke, Ph.D. DEF 14A, filed 2026-05-29. Section “Director Compensation”. As printed: 213,887. View filing ↗
  • Section 08, Werner Cautreels, Ph.D. DEF 14A, filed 2026-05-29. Section “Director Compensation”. As printed: 174,437. View filing ↗
  • Section 08, John Leaman, M.D. DEF 14A, filed 2026-05-29. Section “Director Compensation”. As printed: 87,733. View filing ↗
  • Section 08, Nikolay Savchuk, Ph.D. DEF 14A, filed 2026-05-29. Section “Director Compensation”. As printed: 0. View filing ↗
  • Section 08, Iain Dukes, D. Phil. DEF 14A, filed 2026-05-29. Section “Director Compensation”. As printed: 0. View filing ↗
  • Section 02, Werner Cautreels 2026-07-09. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, D. Iain Dukes 2026-07-09. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Trafford Clarke 2026-07-09. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John Harold Leaman 2026-07-09. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, M. Teresa Shoemaker 2026-07-09. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Charles Nolan Parker 2026-07-09. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Robert Redfield 2026-07-09. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nikolay Savchuk 2026-07-09. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Charles Pauza 2026-07-09. Form 4, filed 2026-07-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jack E. Stover 2026-07-09. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 06, 2025 vote. Form 8-K, filed 2025-11-28. Item 5.07 · say-on-pay result. As reported: 96.36% (votes for as printed: 2,293,949). View filing ↗
  • Section 06, 2024 vote. Form 8-K, filed 2024-11-01. Item 5.07 · say-on-pay result. As reported: 98.84% (votes for as printed: 2,177,245). View filing ↗
  • Section 06, 2023 vote. Form 8-K, filed 2023-08-15. Item 5.07 · say-on-pay result. As reported: 82.3% (votes for as printed: 4,959,016). View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 09b board cost (computed). Computed. Cash 395,625 + equity 63,849 + all other 0 = 459,474, summed across the director compensation table rows.
  • Traws Pharma, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-05-29. CEO total compensation as printed in Traws Pharma, Inc.'s own proxy. As printed: 1,401,924. View filing ↗
Get the full report — $299